pre-IPO PHARMA

COMPANY OVERVIEW

Quark Pharmaceuticals, Inc. is a world leader in discovery and development of novel small interfering RNA, or siRNA, therapeutics for unmet medical needs. Quark’s fully integrated drug discovery and development platform spans the process from therapeutic target identification to drug development.


LOCATION

  • Newark, CA, USA
  • Ness Ziona, , Israel

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Kidney Disease
  • Neurological Disorders
  • Oncology
  • Ophthalmology

  • WEBSITE

    https://quarkpharma.com/


    CAREER WEBSITE

    https://quarkpharma.com/?page_id=12202


    SOCIAL MEDIA


    INVESTORS

    sbi-holdings-group


    PRESS RELEASES


    Sep 2, 2020

    Global RNA-interference (RNAi) Market Growth, Trends and Forecasts to 2025: Focus on Key Players Alnylam Pharmaceuticals, Arrowhead, Quark Pharmaceuticals Inc. and Qiagen NV


    Nov 1, 2017

    Quark Pharmaceuticals, Inc. Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting


    Oct 9, 2017

    Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference


    Jul 27, 2017

    Quark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac Surgery


    Oct 14, 2016

    Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study


    For More Press Releases


    Google Analytics Alternative